APA (7th ed.) Citation

R, B., L, R., A, P., SAM, U., G, R., I, N., . . . M, M. (2023). Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update. Journal of the European Academy of Dermatology and Venereology : JEADV, 37(3), 474. https://doi.org/10.1111/jdv.18693

Chicago Style (17th ed.) Citation

R, Balestri, Rizzoli L, Pedrolli A, Urru SAM, Rech G, Neri I, Girardelli CR, and Magnano M. "Analysis of Current Data on the Use of Topical MTOR Inhibitors in the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex-An Update." Journal of the European Academy of Dermatology and Venereology : JEADV 37, no. 3 (2023): 474. https://doi.org/10.1111/jdv.18693.

MLA (9th ed.) Citation

R, Balestri, et al. "Analysis of Current Data on the Use of Topical MTOR Inhibitors in the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex-An Update." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 37, no. 3, 2023, p. 474, https://doi.org/10.1111/jdv.18693.